Thiamine Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Thiamine dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Thiamine.
Dosing Protocols
Beginner — routine dietary adequacy. Most adults eating a varied Western diet with fortified grains meet the RDA (1.2 mg/day men, 1.1 mg/day women) without supplementation. A basic multivitamin containing 1.5-3 mg thiamine covers any gaps. Pork, whole grains, legumes, nuts, and yeast extract (Marmite/Vegemite) are excellent food sources. No routine testing or supplementation is needed in the absence of risk factors. Pregnancy and lactation RDA is 1.4 mg/day, typically delivered through a prenatal multivitamin.
Intermediate — risk-factor-targeted supplementation. Adults with any of the following risk factors should take thiamine 50-100 mg/day as thiamine HCl with meals indefinitely: chronic alcohol use (any intake above 14 drinks/week for women, 21 for men, or binge pattern); bariatric surgery post-op (lifelong); hyperemesis gravidarum current or prior (continue through pregnancy and for 3 months post-partum at minimum); chronic furosemide or bumetanide therapy for heart failure (100-300 mg/day is used in the Schoenenberger protocol); chronic hemodialysis (dose adjusted by nephrology); inflammatory bowel disease with ongoing malabsorption; chronic total parenteral nutrition (should include B-complex by protocol); refeeding syndrome risk (300 mg IV daily for first 3 days of refeeding, then transition to oral). For diabetic peripheral neuropathy, benfotiamine 150-300 mg/day for 3 months is a reasonable trial based on the BENDIP trial, escalating to 600 mg/day if tolerated and if symptoms warrant; expect modest symptom improvement over weeks. For suspected ongoing alcohol use presenting to medical attention, IV thiamine 100-250 mg in the ED followed by oral 100 mg three times daily for 3-5 days and then 100 mg daily indefinitely is common practice. Always administer thiamine BEFORE glucose in the unresponsive or altered alcoholic patient.
Advanced — acute Wernicke/emergency parenteral therapy and high-dose specialist protocols. For any patient with suspected Wernicke encephalopathy (altered mental status plus any combination of ophthalmoplegia, nystagmus, ataxia, or hypothermia in the alcoholic/malnourished/HG/bariatric setting — and noting that the classic triad is present in fewer than 20% of pathologically confirmed cases, so threshold for empiric treatment should be low): thiamine 500 mg IV over 30 minutes, three times daily for 2-3 days, transitioning to 250 mg IV or IM daily for 5 days, then oral 100 mg three times daily for at least 4-6 weeks and often indefinitely. This is the Thomson/EFNS protocol. Concurrent magnesium repletion is essential (see Magnesium entry). IV glucose, if given, should be after or concurrent with thiamine, not before. Monitor for clinical improvement: ophthalmoplegia typically resolves within 24-48 hours, ataxia over days to weeks, confusion over days. Persistent Korsakoff amnesia is possible despite adequate treatment. For refractory Parkinson disease motor symptoms where standard dopaminergic therapy is optimized but residual symptoms warrant trial of the Costantini approach: intramuscular thiamine 100-200 mg twice weekly is the original protocol, though oral high-dose thiamine (1000-1500 mg/day divided) is sometimes used; evidence is case-series only and the approach remains unproven but low-risk. For thiamine-responsive megaloblastic anemia (TRMA/Rogers syndrome) and biotin-thiamine-responsive basal ganglia disease, thiamine 25-100 mg/day and 10-40 mg/kg/day respectively (with concurrent biotin 5-10 mg/kg/day for the latter), lifelong, under metabolic specialist supervision. For CBS deficiency homocystinuria, thiamine is not the primary vitamin — see the Vitamin B6 entry for the pyridoxine-responsive/unresponsive discussion. All high-dose specialist protocols require specialist supervision, laboratory monitoring, and consideration of concomitant B-complex repletion.
Commonly Stacked With
Thiamine stacks with several other compounds in biologically meaningful ways. The B-complex co-administration rationale: thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), pyridoxine (B6), biotin (B7), folate (B9), and cobalamin (B12) all participate in overlapping metabolic pathways, and several clinical products deliver them together because single-vitamin deficiency in isolation is less common than multi-deficiency in alcoholism, malnutrition, and malabsorption. The Vitamin B6, Folate, and Vitamin B12 entries cover the specific homocysteine-lowering partnership; thiamine sits outside this triad but is frequently co-supplemented because of shared clinical contexts. Magnesium is an important co-factor: thiamine pyrophosphokinase (TPK1), which converts thiamine to TPP, requires Mg2+ for activity, and PDH and αKGDH both require magnesium for full enzymatic function. Co-depletion of thiamine and magnesium is common in alcoholism and refeeding syndrome, and attempts to replete thiamine in magnesium-deficient patients may be suboptimal — see the Magnesium entry for the broader discussion. Alpha-lipoic acid is the other essential cofactor of PDH, αKGDH, and BCKDH, and co-supplementation has theoretical appeal for any condition involving these complexes; see the Alpha-Lipoic Acid entry. Biotin partners with thiamine in biotin-thiamine-responsive basal ganglia disease at therapeutic doses; the two vitamins have otherwise largely separate biochemistry. Benfotiamine + B-complex: the German "Milgamma" product combines benfotiamine with B6 and B12 for diabetic neuropathy, with Stracke 2008 showing benefit over 12 weeks. Sulbutiamine is a separate thiamine-derivative nootropic discussed in its own entry; stacking plain thiamine with sulbutiamine adds little because sulbutiamine ultimately delivers thiamine. Coenzyme Q10 + thiamine is a reasonable mitochondrial bioenergetic stack for heart failure and may address complementary aspects of oxidative phosphorylation; see the CoQ10 entry. Choline and thiamine overlap in neurotransmitter precursor roles (thiamine indirectly via TPP-dependent metabolic support of cholinergic neurons; choline directly via acetyl-CoA + choline → acetylcholine); see the Choline entry. Iron deficiency and thiamine deficiency can co-occur in malnutrition contexts and can produce overlapping fatigue symptoms; see the Iron entry. The Marik HAT protocol (hydrocortisone + ascorbic acid + thiamine) for sepsis, once enthusiastically combined, is no longer recommended as standard after negative confirmatory RCTs, but the underlying components remain individually indicated where appropriate. For Parkinson disease the Italian Costantini protocol has occasionally been combined with CoQ10 and other mitochondrial supports, though evidence for any component remains limited. The cleanest stacking summary: thiamine pairs naturally with magnesium (cofactor for phosphorylation), with lipoic acid (shared PDH/αKGDH cofactor role), with the broader B-complex in clinical contexts of multi-deficiency, and with benfotiamine + B6 + B12 specifically for diabetic neuropathy. See Sulbutiamine for the lipophilic nootropic derivative, Magnesium for the kinase cofactor partnership, Alpha-Lipoic Acid for parallel cofactor roles, CoQ10 and Creatine for mitochondrial bioenergetic context, Vitamin B6, Folate, Vitamin B12, and Choline for the broader B-complex and one-carbon metabolism network, Iron for co-deficiency context, and Omega-3 fatty acids for a cardiovascular co-support framework.
Side Effects & Safety
Contraindications
There are no absolute contraindications to oral thiamine supplementation at RDA-range or therapeutic doses; the compound is one of the safest vitamins known. Relative contraindications and cautions: **Known hypersensitivity** to thiamine or to excipients in a particular formulation is an absolute contraindication to re-administration of the offending product. **IV thiamine with prior anaphylactoid reaction** — switch to oral or IM route, or use very slow IV infusion with resuscitation capability if IV is essential. **Glucose administration before thiamine** in suspected deficiency — not a contraindication to thiamine, but the order matters: give thiamine first or concurrently with glucose in the altered alcoholic or malnourished patient. **Pregnancy** is not a contraindication; thiamine at RDA or therapeutic doses is safe and required in pregnancy. **Hyperemesis gravidarum** is an indication rather than contraindication; give 100 mg thiamine IV or IM with IV fluids to prevent Wernicke's and fetal demise. **Breastfeeding** is not a contraindication at RDA to therapeutic doses. **Pediatric use** is appropriate under pediatric supervision; infantile beriberi is treated with 25-50 mg IV/IM daily. **Renal failure** is not a contraindication but thiamine is removed by hemodialysis so maintenance doses should be timed after dialysis or increased on dialysis days. **Hepatic failure** is not a contraindication; alcoholic liver disease is a strong indication for thiamine supplementation. **Known thiamine-responsive inborn errors of metabolism** (TRMA, BTBGD) are indications for high-dose thiamine, not contraindications. There are no clinically important absolute drug-drug contraindications. The overall safety profile is such that the principal clinical risk of thiamine is failure to give it when indicated (under-recognition of Wernicke's) rather than any risk from giving it when not indicated.
Additional Notes
The adult RDA for thiamine is 1.2 mg/day for men, 1.1 mg/day for women, 1.4 mg/day in pregnancy, 1.4 mg/day in lactation. Pediatric RDAs scale from 0.2 mg/day in infants to 0.9-1.2 mg/day in adolescents. There is no formally established tolerable upper intake level because of the absence of toxicity signal across the dose range studied. Oral absorption is saturable via THTR2 at approximately 5-10 mg per single administration, so higher daily doses should be divided into multiple administrations or delivered via lipophilic derivatives (benfotiamine) that bypass saturable transport. Thiamine HCl is the standard oral supplement form, 50-100 mg tablets are widely available, and the compound is inexpensive. Benfotiamine 150 mg and 300 mg capsules are available; typical daily doses for diabetic neuropathy are 300-600 mg divided into 2-3 doses. IV thiamine is supplied as 100 mg/mL solution in 1-2 mL vials; administration is typically diluted in 100 mL normal saline over 30 minutes. IM thiamine uses the same solution. Timing with meals is preferred for oral thiamine to reduce the small GI upset potential and to mimic physiologic delivery. Thiamine has a plasma half-life of 1-12 hours depending on assay method; whole-body half-life is 10-20 days. Thiamine is destroyed by cooking in alkaline conditions, by sulfites (processed meats, some wines), and by thiaminases present in raw fish and certain shellfish (cooking inactivates thiaminases). Coffee and tea contain polyphenols that modestly inhibit thiamine absorption in laboratory studies but this is not clinically relevant at typical intakes. For suspected deficiency, empiric treatment is reasonable rather than waiting for laboratory confirmation — Wernicke encephalopathy is a clinical emergency. For monitoring status in chronic supplementation, erythrocyte transketolase activity with TPP stimulation is the functional assay; plasma TPP by HPLC is increasingly available.
Frequently Asked Questions
What is the recommended Thiamine dosage?
Dosage for Thiamine varies by protocol. Consult a qualified healthcare provider.
How often should I take Thiamine?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Thiamine need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Thiamine side effects?
Thiamine is among the safest vitamins known. At RDA-range dietary intake and even at pharmacologic oral doses (hundreds of milligrams per day), thiamine has no characteristic dose-limiting toxicity. The body does not substantially store thiamine, excess is rapidly excreted in the urine, and no well-documented organ toxicity has been associated with chronic high-dose oral use at supplement range. This is distinctly different from vitamin B6 (sensory neuropathy at chronic multi-hundred-milligram doses; see the [Vitamin B6](/compound/vitamin-b6) entry) or fat-soluble vitamins (hypervitaminosis A, D toxicity) — thiamine is one of the most forgiving water-soluble vitamins at supraphysiologic doses. The Institute of Medicine did not establish a formal tolerable upper intake level for thiamine citing the lack of adverse effect signal across human exposure data. The principal safety concern with thiamine is **intravenous anaphylaxis**. Rare but well-documented hypersensitivity reactions to IV thiamine have produced case reports of anaphylaxis and death since the 1940s. Stephen and Hanson's classic series documented the phenomenon, and it is the reason that hospital protocols administer IV thiamine over 30 minutes rather than as rapid push, and usually in the presence of resuscitation capability. The incidence of serious IV thiamine reactions is extremely low (~1 per million or rarer), and the clinical benefit of IV thiamine in suspected Wernicke's vastly outweighs this risk — but emergency medicine practice continues to include resuscitation-ready IV administration. Intramuscular thiamine rarely causes local injection site reactions and has a lower anaphylaxis risk than IV administration. Oral thiamine has no reported anaphylaxis risk. Other reported thiamine effects at high-dose use: nausea, restlessness, mild flushing or warmth sensation with IV administration, rare urticarial skin reactions, sweating, and transient tachycardia. Chronic oral high-dose thiamine at hundreds of milligrams per day has not been linked to any organ toxicity in published case series. **Glucose-before-thiamine caution in alcoholics and the malnourished.** This is a pharmacologic interaction of the first importance. In a thiamine-depleted patient, IV glucose administration rapidly drives pyruvate into the PDH step and α-ketoglutarate into the αKGDH step, both of which require TPP; the sudden demand can precipitate acute Wernicke encephalopathy within hours in a patient who was compensated before the glucose load. For this reason, any alcoholic or malnourished patient receiving IV glucose should receive thiamine concurrently or before — the standard ED teaching is "thiamine before glucose" in the unresponsive alcoholic patient, with both often given together in practice. **Benfotiamine side effects** mirror thiamine's with occasional mild GI upset, bodily warmth, and rare skin reactions. Benfotiamine's S-benzoate liberation has been theoretically linked to benzoate accumulation concerns in patients with urea cycle defects, though this is rarely clinically relevant at standard doses. **Sulbutiamine side effects** are discussed in the [Sulbutiamine](/compound/sulbutiamine) entry and include mild hyperactivity, insomnia, and, rarely, hypomanic reactions in bipolar-spectrum patients — effects not typically seen with plain thiamine. **Drug interactions.** Thiamine as a vitamin has few clinically important drug interactions. Loop diuretics (furosemide, bumetanide) increase urinary thiamine loss — this is a reason to repelete, not a contraindication. 5-Fluorouracil and other fluoropyrimidine chemotherapeutics can precipitate Wernicke-like syndromes in thiamine-depleted patients; prophylactic thiamine is sometimes recommended during chemotherapy. Chronic alcohol obviously depletes thiamine through multiple mechanisms. Phenobarbital, phenytoin, and carbamazepine can modestly lower thiamine levels. Oral contraceptives do not substantially affect thiamine. **Pregnancy and lactation.** RDA-range thiamine (1.4 mg/day) is safe and recommended. Hyperemesis gravidarum cases require prophylactic thiamine at 100 mg IM/IV to prevent maternal Wernicke's and fetal demise. Pyridoxine-doxylamine antiemetic (Diclegis) does not replace thiamine in HG. Breastfeeding safety at RDA range is established; high-dose maternal thiamine has not been associated with infant adverse effects. **Pediatric use.** RDA-range thiamine is essential in infancy. Infantile beriberi is a historical pediatric emergency largely abolished by grain fortification but reported in breastfed infants of thiamine-deficient mothers, in severely thiamine-poor infant formulas (the 2003 Israel formula scandal), and in medical feeding errors. Treatment is IV/IM thiamine 25-50 mg daily for several days with transition to oral maintenance. Biotin-thiamine-responsive basal ganglia disease is treated with high-dose thiamine and biotin from diagnosis. TRMA syndrome is managed lifelong with thiamine 25-100 mg/day. **Laboratory monitoring.** Plasma thiamine (via HPLC) and erythrocyte transketolase activity with TPP stimulation are the clinical tests of thiamine status. Urinary thiamine is useful for assessing intake over the preceding 24-48 hours. In acute Wernicke's, clinical diagnosis takes priority over laboratory confirmation — empiric treatment is initiated based on clinical suspicion. The cleanest safety summary: thiamine is extraordinarily safe at oral doses up to hundreds of milligrams per day; IV thiamine carries rare anaphylaxis risk mitigated by slow infusion and resuscitation-ready administration; the major interaction to know is "thiamine before glucose" in suspected deficiency; and most clinical use is limited by under-recognition of deficiency rather than by toxicity.
Where can I buy Thiamine?
Visit our vendor directory to find trusted sources for Thiamine.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
